Patients with multiple sclerosis treated with natalizumab may rarely develop progressive multifocal leukoencephalopathy (PML), a serious and often fatal disease caused by infection with JC virus. The ...
Multiple sclerosis patients using Biogen Idec (NASDAQ:BIIB) drug Tysabri now have access to the first test that can help determine their risk for developing a rare but potentially fatal brain ...
COPENHAGEN, Denmark — A new test that compares JC virus (JCV) antibody levels in cerebrospinal fluid (CSF) with those in serum might be a useful complementary tool in the diagnostic workup for ...
Sept. 10 -- WEDNESDAY, Sept. 9 (HealthDay News) -- Scientists may have discovered part of the reason why Tysabri, a drug used to treat multiple sclerosis, may lead to the development of a rare but ...
Another case of a potentially fatal brain infection has been reported in a patient taking the multiple sclerosis drug Tysabri, the biotech who developed the drug announced yesterday. This is the ...
There is currently no cure for Multiple Sclerosis (MS). Patients rarely do well with no therapy at all, and it is generally recommended that patients with a confident diagnosis of MS begin treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results